Abbott Plans to Spin Off Its Nutrition Business

Abbott plans to spin off its nutrition business, which generates $8.5bn in annual revenue, into an independent publicly traded company by the end of 2027. The move aims to allow both entities to focus on their respective markets. Abbott's remaining business will have $42bn in revenue and focus on medical devices, diagnostics, and pharmaceuticals. The transaction is subject to regulatory approvals and will not impact Abbott's 2026 and 2027 guidance.

Original reporting
Published Oct 21, 2026, 1:05 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Oct 21, 2026, 1:26 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefCorporate actions
Primary signal
$ABT
Neutral
high confidence
Mentioned
$ABT
Relevance
7/10
AlphAI data visualization · based on marketscreener.com
Decision brief

The 30-second read

$ABTNeutralMed
01

Why it matters

The announced spin‑off creates a standalone nutrition company, distributing shares to existing Abbott shareholders, and is expected to be completed by end‑2027.

02

Market read

A major corporate restructuring that could reshape Abbott's valuation and create a new listed nutrition player.

03

What to watch

Regulatory approvals and timing delays could postpone value realization; the new entity may face competitive pressures in the nutrition space.

Relevance 7/10Novelty 8/10Timing: immediate – news released today

Background

Abbott Laboratories (ABT) is a diversified health‑care company with major businesses in medical devices, diagnostics, and pharmaceuticals. The nutrition segment accounts for ~19% of sales.

Company-level read

Ticker impact

$ABTNeutralHigh confidence
Context

Abbott announced a plan to spin off its nutrition business into a separate publicly traded company, creating a new entity with ~$8.5 bn revenue.

Expected impact

possible modest pressure on ABT as investors assess the split, with upside potential if the nutrition spin‑off is valued favorably.

Evidence & confidence

Spin‑offs are material corporate actions; the disclosed revenue size and timeline are new information, allowing traders to position ahead of the separation.

Market effects

Nutrition segment may become a pure‑play health‑nutrition stock, affecting peer comparisons in consumer health and specialty nutrition sectors.

Abbott's global footprint means the spin‑off could attract interest from investors focused on emerging‑market nutrition demand.

Large‑cap spin‑off with $8.5 bn revenue is noteworthy for global equity markets and may influence index weightings.

Counterpoint

The spin‑off could dilute Abbott's earnings visibility and increase execution risk, potentially weighing on ABT if integration costs rise.

Key entities

  • Abbott Laboratories

    US‑listed health‑care conglomerate planning the spin‑off.

  • Robert B. Ford

    CEO of Abbott who announced the separation.

Related articles

$PHGMed

New Study Shows How Hybrid Imaging Can Guide Coronary Treatment Decisions

Conavi Medical (TSXV: CNVI, OTCQB: CNVIF) received FDA 510(k) clearance for its hybrid imaging system, combining IVUS and OCT. The company reported first U.S. commercial placement, early clinical benefits, and extended credit facilities. Peer-reviewed research supports hybrid imaging for coronary treatment decisions. Conavi aims to expand physician adoption and hospital placements.

$ABTMed

Here's How Abbott's EP Business Is Shaping Up for the Rest of 2026

Abbott's (ABT) Medical Devices segment saw 8% sales growth in Q3 2026, driven by Electrophysiology (EP) products. EP sales grew mid-to-high-teens globally and over 20% in the U.S. Volt PFA catheter adoption accelerated post-U.S. launch. Abbott received FDA approval for TactiFlex Duo and CE Mark for Amulet 360. Japan launch expected in Q4. LAA market weakness is a headwind. Thermo Fisher (TMO) and Insulet (PODD) also reported Q3 earnings.

$ABTMed

Can UltiSynq Lead Boost Abbott's Cardiac Rhythm Management Business?

Abbott's UltiSynq defibrillation lead received FDA and CE Mark approvals, backed by successful trial results. The device aims to improve cardiac rhythm management, with 98.5% successful implantation and 97.5% complication-free rate at three months. Abbott also received FDA's breakthrough device designation. Medtronic and Boston Scientific provided updates on their cardiac devices. Abbott shares have declined 12.2% over the past year, trading at a forward P/S of 3.60X.

$ABTMedAI 9/10

Abbott Touts Favorable Outcomes In Cardiovascular Device Trials

Abbott Laboratories (ABT) presented positive clinical trial results for two cardiovascular devices at a conference. The Amulet 360 LAA Occluder showed 96.3% complete closure in patients, with low complication rates. The SonicForce System achieved 97% procedural success in treating calcified coronary arteries. ABT shares rose 2.55% to $108.91.